<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">LS5wtnHMxgNFyzTtgVJp7Xv</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000400011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200411</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000400011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o da seguran&#231;a do teste de caminhada dos 6 minutos em pacientes no pr&#233;-transplante card&#237;aco</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cipriano Jr</surname>
            <given-names>Gerson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yuri</surname>
            <given-names>Darlene</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernardelli</surname>
            <given-names>Graziella Fran&#231;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mair</surname>
            <given-names>Vanessa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buffolo</surname>
            <given-names>Enio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Branco</surname>
            <given-names>Jo&#227;o Nelson Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Universidade de S&#227;o Paulo </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>4</issue>
      <fpage>312</fpage>
      <lpage>319</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>11</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>07</day>
          <month>05</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>07</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O teste de caminhada dos 6 minutos (TC6) tem sido utilizado como forma de avalia&#231;&#227;o da capacidade funcional, estadiamento cl&#237;nico e progn&#243;stico cardiovascular. A seguran&#231;a e o impacto metab&#243;lico s&#227;o pouco descritos na literatura, principalmente em pacientes com insufici&#234;ncia card&#237;aca grave, com indica&#231;&#227;o cl&#237;nica para transplante cardiovascular. OBJETIVO: Avaliar a ocorr&#234;ncia de arritmias e altera&#231;&#245;es cardiovasculares durante o TC6. Correlacionar o desempenho no TC6 com o estadiamento cl&#237;nico e progn&#243;stico cardiovascular. M&#201;TODOS: Doze pacientes, sendo 10 masculinos, com idade de 52 &#177; 8 anos, foram submetidos &#224; avalia&#231;&#227;o inicial. Realizaram o TC6 com monitoramento eletrocardiogr&#225;fico por telemetria, sinais vitais e lactato. Foram acompanhados por 12 meses. RESULTADOS: Os pacientes percorreram 399,4 &#177; 122,5 (D, m), atingindo um esfor&#231;o percebido (EP) de 14,3 &#177; 1,5 e varia&#231;&#227;o de 34% na freq&#252;&#234;ncia card&#237;aca basal. Dois pacientes apresentaram arritmia de maior gravidade pr&#233;-TC6 e n&#227;o pioraram ante o esfor&#231;o, quatro tiveram eleva&#231;&#227;o significativa nos n&#237;veis de lactato sang&#252;&#237;neo (&gt;5 mmol/dl), e tr&#234;s interromperam o exame. A dist&#226;ncia percorrida evidenciou correla&#231;&#227;o com a fra&#231;&#227;o de eje&#231;&#227;o (%) e classifica&#231;&#227;o funcional (NYHA). Ap&#243;s 12 meses de seguimento, tr&#234;s pacientes foram a &#243;bito, e reinternaram-se sete por descompensa&#231;&#227;o card&#237;aca. A rela&#231;&#227;o (D/EP) e freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o no segundo minuto (FCR2, bpm) foram inferiores no grupo-&#243;bito. CONCLUS&#195;O: O comportamento cl&#237;nico e eletrocardiogr&#225;fico sugere que o m&#233;todo &#233; seguro, mas pode ser considerado de alta intensidade para alguns pacientes com insufici&#234;ncia card&#237;aca grave. Vari&#225;veis relacionadas ao desempenho no TC6 podem estar associadas com a mortalidade no seguimento de um ano.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Caminhada</kwd>
        <kwd>avalia&#231;&#227;o em sa&#250;de</kwd>
        <kwd>efetividade</kwd>
        <kwd>insufici&#234;ncia card&#237;aca</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>23</day>
        <month>06</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> TRANSPLANTE CARD&#205;ACO - CIRURGIA</p>
    <p>
      <bold>Avalia&#231;&#227;o da seguran&#231;a do teste de caminhada dos 6 minutos em pacientes no pr&#233;-transplante card&#237;aco</bold>
    </p>
    <p>
      <bold>Gerson Cipriano Jr; Darlene Yuri; Graziella Fran&#231;a Bernardelli; Vanessa Mair; Enio Buffolo; Jo&#227;o Nelson Rodrigues Branco</bold>
    </p>
    <p> Universidade Federal de S&#227;o Paulo, Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="add1">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> O teste de caminhada dos 6 minutos (TC6) tem sido utilizado como forma de avalia&#231;&#227;o da capacidade funcional, estadiamento cl&#237;nico e progn&#243;stico cardiovascular. A seguran&#231;a e o impacto metab&#243;lico s&#227;o pouco descritos na literatura, principalmente em pacientes com insufici&#234;ncia card&#237;aca grave, com indica&#231;&#227;o cl&#237;nica para transplante cardiovascular. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a ocorr&#234;ncia de arritmias e altera&#231;&#245;es cardiovasculares durante o TC6. Correlacionar o desempenho no TC6 com o estadiamento cl&#237;nico e progn&#243;stico cardiovascular. </p>
    <p><bold>M&#201;TODOS:</bold> Doze pacientes, sendo 10 masculinos, com idade de 52 &#177; 8 anos, foram submetidos &#224; avalia&#231;&#227;o inicial. Realizaram o TC6 com monitoramento eletrocardiogr&#225;fico por telemetria, sinais vitais e lactato. Foram acompanhados por 12 meses. </p>
    <p><bold>RESULTADOS:</bold> Os pacientes percorreram 399,4 &#177; 122,5 (D, m), atingindo um esfor&#231;o percebido (EP) de 14,3 &#177; 1,5 e varia&#231;&#227;o de 34% na freq&#252;&#234;ncia card&#237;aca basal. Dois pacientes apresentaram arritmia de maior gravidade pr&#233;-TC6 e n&#227;o pioraram ante o esfor&#231;o, quatro tiveram eleva&#231;&#227;o significativa nos n&#237;veis de lactato sang&#252;&#237;neo (&gt;5 mmol/dl), e tr&#234;s interromperam o exame. A dist&#226;ncia percorrida evidenciou correla&#231;&#227;o com a fra&#231;&#227;o de eje&#231;&#227;o (%) e classifica&#231;&#227;o funcional (NYHA). Ap&#243;s 12 meses de seguimento, tr&#234;s pacientes foram a &#243;bito, e reinternaram-se sete por descompensa&#231;&#227;o card&#237;aca. A rela&#231;&#227;o (D/EP) e freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o no segundo minuto (FCR2, bpm) foram inferiores no grupo-&#243;bito. </p>
    <p><bold>CONCLUS&#195;O:</bold> O comportamento cl&#237;nico e eletrocardiogr&#225;fico sugere que o m&#233;todo &#233; seguro, mas pode ser considerado de alta intensidade para alguns pacientes com insufici&#234;ncia card&#237;aca grave. Vari&#225;veis relacionadas ao desempenho no TC6 podem estar associadas com a mortalidade no seguimento de um ano. </p>
    <p><bold>Palavras-chave:</bold> Caminhada, avalia&#231;&#227;o em sa&#250;de, efetividade, insufici&#234;ncia card&#237;aca.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca refrat&#225;ria &#233; condi&#231;&#227;o terminal de diversas cardiopatias, caracterizada por piora do quadro cl&#237;nico e mortalidade<sup>1</sup>. A fal&#234;ncia de mecanismos compensat&#243;rios para manuten&#231;&#227;o de d&#233;bito card&#237;aco favorece a desnutri&#231;&#227;o energ&#233;tico-prot&#233;ica e redu&#231;&#227;o do leito vascular e da capacidade funcional<sup>2,3</sup>. O transplante card&#237;aco tem sido uma op&#231;&#227;o terap&#234;utica eficiente, melhorando a sobrevida e a capacidade funcional (CF), no entanto, ap&#243;s indica&#231;&#227;o cl&#237;nica, o acompanhamento terap&#234;utico na fase pr&#233;-transplante &#233; delicado e oneroso<sup>4,5</sup>. </p>
    <p>A avalia&#231;&#227;o cardiopulmonar &#233; o m&#233;todo de maior acur&#225;cia na avalia&#231;&#227;o e no acompanhamento da capacidade funcional, no entanto sua realiza&#231;&#227;o peri&#243;dica &#233; de dif&#237;cil execu&#231;&#227;o, podendo dificultar um controle mais detalhado dos pacientes nessa condi&#231;&#227;o cl&#237;nica<sup>6,7</sup>. Nesses casos, o teste de caminhada dos 6 minutos (TC6) pode ser indicado como m&#233;todo alternativo simplificado, reprodut&#237;vel e de baixo custo<sup>8</sup> para avalia&#231;&#227;o da toler&#226;ncia ao exerc&#237;cio, fornecendo estimativa indireta quanto a diversos aspectos, como estadiamento cl&#237;nico<sup>9-16</sup>, resposta a interven&#231;&#245;es e qualidade de vida<sup>17,18</sup>, especialmente naqueles com maior redu&#231;&#227;o da capacidade funcional<sup>19-24</sup>. </p>
    <p>O conhecimento cient&#237;fico mais espec&#237;fico quanto &#224; seguran&#231;a e os principais ajustes sist&#234;micos ante o TC6 nos pacientes com insufici&#234;ncia card&#237;aca (ICC) refrat&#225;ria poderiam minimizar o aparecimento de respostas cl&#237;nicas adversas<sup>25</sup>, como sinais de intoler&#226;ncia ao exerc&#237;cio, arritmias e complica&#231;&#245;es secund&#225;rias, especialmente presentes em condi&#231;&#245;es de redu&#231;&#227;o no suprimento de oxig&#234;nio mioc&#225;rdico, muito freq&#252;entes nessa popula&#231;&#227;o<sup>26,27</sup>. </p>
    <p>O presente estudo tem por objetivo avaliar as respostas cardiovasculares perante o TC6 e suas poss&#237;veis rela&#231;&#245;es com o estadiamento cl&#237;nico e progn&#243;stico cardiovascular. Dessa forma, acreditamos contribuir para o aperfei&#231;oamento do controle e da prescri&#231;&#227;o das interven&#231;&#245;es nessa popula&#231;&#227;o cardiopata que aguarda o transplante card&#237;aco. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Participantes do estudo</bold>
    </p>
    <p>Doze pacientes (idade 52 &#177; 8 anos, 10 masculino e 2 do feminino) do ambulat&#243;rio de transplante card&#237;aco do hospital universit&#225;rio da Universidade Federal de S&#227;o Paulo pertenciam ao grupo de estudo. Os pacientes apresentavam diagn&#243;stico cl&#237;nico de insufici&#234;ncia card&#237;aca refrat&#225;ria, com indica&#231;&#227;o eletiva para transplante card&#237;aco. As principais etiologias da insufici&#234;ncia card&#237;aca estavam relacionadas a miocardiopatias isqu&#234;micas (58,3%) e idiop&#225;ticas (25%). Oito pacientes (67,7%) estavam em classes funcionais III e IV (NYHA), dez (83,3%) com comorbidades associadas e nove (75%) j&#225; haviam realizado procedimentos cardiovasculares pr&#233;vios (cinco cirurgias de revasculariza&#231;&#227;o mioc&#225;rdica e quatro angioplastia transluminal) (<xref ref-type="table" rid="tab1">tab. 1</xref>). A pesquisa contou com o pr&#233;vio consentimento dos pacientes e foi aprovada pelo Comit&#234; de &#201;tica e Pesquisa. </p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt01.jpg"/></table-wrap>
    <p>
      <bold>Desenho e protocolo</bold>
    </p>
    <p>O estudo caracterizado como uma coorte prospectiva contou com quinze pacientes, sendo tr&#234;s exclu&#237;dos por descompensa&#231;&#227;o cardiovascular e doze submetidos ao protocolo. O estudo foi composto de uma avalia&#231;&#227;o cl&#237;nica inicial, com informa&#231;&#245;es sobre o estadiamento cl&#237;nico e cardiovascular, seguido de teste de caminhada dos 6 minutos (TC6). Na seq&#252;&#234;ncia, os pacientes foram acompanhados clinicamente por 12 meses ap&#243;s o TC6. </p>
    <p>
      <bold>Avalia&#231;&#227;o cl&#237;nica inicial</bold>
    </p>
    <p>Constou de informa&#231;&#245;es referentes &#224; avalia&#231;&#227;o cl&#237;nica e ecocardiogr&#225;fica como: etiologia, presen&#231;a de comorbidades e procedimentos cardiovasculares pr&#233;vios, tratamento cl&#237;nico e fun&#231;&#227;o cardiovascular (fra&#231;&#227;o de eje&#231;&#227;o (%)) e classe funcional (NYHA)<sup>28</sup>. Os pacientes tamb&#233;m foram avaliados quanto ao impacto da insufici&#234;ncia card&#237;aca na qualidade de vida, utilizando um question&#225;rio espec&#237;fico para insufici&#234;ncia card&#237;aca, denominado <italic>Minnesota Living with Heart Failure questionnaire</italic> (MLHF)<sup>18</sup>. </p>
    <p>
      <bold>Teste de caminhada dos 6 minutos</bold>
    </p>
    <p>Os pacientes foram submetidos inicialmente a exame de eletrocardiografia em repouso, para verifica&#231;&#227;o da exist&#234;ncia de arritmias. O TC6 foi realizado de acordo com as diretrizes da Associa&#231;&#227;o Americana de Reabilita&#231;&#227;o Cardiovascular e Pulmonar (AACVPR)<sup>29</sup> e diretrizes para realiza&#231;&#227;o de exames ergom&#233;tricos da Sociedade Brasileira de Cardiologia (SBC)<sup>7</sup>, em pista circular de 30 metros de comprimento, sem acompanhamento e recebendo apenas as orienta&#231;&#245;es padronizadas a cada minuto. Os pacientes foram monitorados quanto &#224; freq&#252;&#234;ncia card&#237;aca (FC, bpm), freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o (FCR, bpm), press&#227;o arterial (PA, mmHg), satura&#231;&#227;o perif&#233;rica de oxig&#234;nio (SpO<sub>2</sub>, %) e escala de percep&#231;&#227;o de esfor&#231;o (EP)<sup>30</sup>. Tamb&#233;m foram monitorados continuamente quanto &#224; eletrocardiografia por telemetria (Quark T12, modelo CO9055-32-99, Cosmed<sup>&#174;</sup>, It&#225;lia), possibilitando-nos a monitoriza&#231;&#227;o instant&#226;nea de eventos que indicassem a suspens&#227;o do exame. Mensuraram-se ainda os valores de lactato perif&#233;rico antes e ap&#243;s o TC6. A medida perif&#233;rica basal foi realizada ap&#243;s per&#237;odo m&#237;nimo de 1 hora sem a realiza&#231;&#227;o de exerc&#237;cios e/ou atividades de esfor&#231;o, e a final, imediatamente ap&#243;s o t&#233;rmino do teste.</p>
    <p>
      <bold>Seguimento ap&#243;s 12 meses do TC6</bold>
    </p>
    <p>Os pacientes foram acompanhados por um per&#237;odo de 12 meses ap&#243;s realiza&#231;&#227;o de TC6, a fim de observarmos informa&#231;&#245;es quanto &#224; evolu&#231;&#227;o cl&#237;nica, tais como reinterna&#231;&#227;o, descompensa&#231;&#227;o do quadro cl&#237;nico e mortalidade.</p>
    <p>
      <bold>M&#233;todo estat&#237;stico</bold>
    </p>
    <p>Os dados cont&#237;nuos param&#233;tricos foram representados por m&#233;dia e desvio padr&#227;o e comparados ao longo do tempo pela Anova para medidas repetidas, com p&#243;s-teste de Newman-Keuls, para mais de dois tempos; quando n&#227;o, pelo teste <italic>t </italic>de <italic>Student</italic>. Os n&#227;o-param&#233;tricos foram representados por mediana e percentil e comparados ao longo do tempo pelo teste de Friedman com p&#243;s-teste de Muller-Dunn, para mais de dois tempos, quando n&#227;o, pelo Wilcoxon. Os dados categ&#243;ricos foram representados por freq&#252;&#234;ncia absoluta (n) e freq&#252;&#234;ncia relativa (%) e comparados ao longo do tempo pelo teste de Mc'Nemar; nos caso de grupos independentes, utilizou-se qui-quadrado. Para verifica&#231;&#227;o de associa&#231;&#227;o entre as vari&#225;veis do teste com o estadiamento cl&#237;nico e cardiovascular, utilizou-se a an&#225;lise de correla&#231;&#227;o linear de Pearson, em que se admitiram os seguintes valores de concord&#226;ncia: &gt; 0,75 excelente, &lt; 0,40 pobre e entre 0,40 e 0,75 moderada. Foi considerado para todo o estudo risco alfa menor ou igual a 5%, e risco beta de menor ou igual a 20%. </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Ocorr&#234;ncia de arritmias</bold>
    </p>
    <p>A ocorr&#234;ncia de arritmia foi classificada de tr&#234;s formas durante o TC6. A an&#225;lise descritiva, representada pelo tipo de arritmia, n&#227;o revelou exacerba&#231;&#227;o ante o TC6 (p: 0,228). Nem a an&#225;lise qualitativa quanto &#224; mudan&#231;a no estadiamento de risco durante o teste evidenciou exacerba&#231;&#227;o, utilizando classifica&#231;&#245;es quanto &#224; origem (p: 0,546) ou tipo (0,735) (<xref ref-type="table" rid="a11tab02m">tab. 2</xref>).</p>
    <p content-type="asset">
      <table-wrap id="a11tab02m">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt02.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Comportamento m&#225;ximo ante o TC6</bold>
    </p>
    <p>Ao contr&#225;rio da SpO<sub>2</sub> e PA, que n&#227;o demonstraram altera&#231;&#245;es significativas ante o esfor&#231;o, a FC ajustou-se de forma eficiente e fisiol&#243;gica, caracterizando-se como principal respons&#225;vel pelo ajuste positivo do duplo produto card&#237;aco (<xref ref-type="table" rid="tab3">tab. 3</xref>).</p>
    <table-wrap id="tab3">
      <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt03.jpg"/></table-wrap>
    <p>A dist&#226;ncia m&#233;dia percorrida foi de 399,4 &#177; 122,5, com importante incremento no esfor&#231;o percebido (14 &#177; 1,5)<sup>31</sup> e evidente varia&#231;&#227;o no n&#237;vel de lactato. Neste &#250;ltimo, quatro indiv&#237;duos atingiram n&#237;veis acima de 4 mmol/l, sugerindo maior utiliza&#231;&#227;o de metabolismo anaer&#243;bio durante a atividade. Outros tr&#234;s indiv&#237;duos interromperam o teste precocemente: o primeiro por dispn&#233;ia, tontura, palpita&#231;&#227;o e dor em membros inferiores (MMII), aos 285 segundos; o segundo por dor em MMII, aos 242 segundos, e o terceiro por dor pr&#233;-cordial, aos 180 minutos. Os dois &#250;ltimos n&#227;o apresentaram altera&#231;&#227;o eletrocardiogr&#225;fica caracter&#237;stica de isquemia (<xref ref-type="table" rid="tab3">tab. 3</xref>). Ap&#243;s interrup&#231;&#227;o, os pacientes poderiam dar continuidade ao exame at&#233; que se completassem os 360 minutos previstos, s&#243; ent&#227;o a dist&#226;ncia total percorrida foi considerada.</p>
    <p>
      <bold>Estadiamento cl&#237;nico e progn&#243;stico cardiovascular</bold>
    </p>
    <p>Tr&#234;s pacientes foram a &#243;bito no per&#237;odo de 12 meses de seguimento, dois deles ap&#243;s reinterna&#231;&#227;o por descompensa&#231;&#227;o cardiovascular, aguardando o transplante cardiovascular, e um por rejei&#231;&#227;o tardia ap&#243;s transplante cardiovascular. Os pacientes mantiveram controle peri&#243;dico convencional em ambulat&#243;rio de acompanhamento cl&#237;nico, mas apenas dois foram transplantados durante o per&#237;odo de segmento, sendo o tempo m&#233;dio de espera na &#233;poca de 21,5 &#177; 4,95 meses. Nesse per&#237;odo, seis (50%), manifestaram epis&#243;dios de piora do estadiamento cl&#237;nico, necessitando de interna&#231;&#227;o hospitalar, sendo cinco (41,67%) por descompensa&#231;&#227;o da insufici&#234;ncia card&#237;aca e um (8,33%) por insufici&#234;ncia renal. </p>
    <p>O estudo de correla&#231;&#227;o de todas as vari&#225;veis obtidas no TC6 revelou associa&#231;&#227;o apenas entre a dist&#226;ncia percorrida e a gravidade da arritmia ao final do TC6, com a FE (Fra&#231;&#227;o de Ejec&#231;&#227;o) (R: 0,7 e -0,83) e CF (Classe Fucional) (R: 0,73 e 0,73) (<xref ref-type="fig" rid="fig01">fig. 1</xref>). A qualidade de vida demonstrou-se moderadamente reduzida (31 &#177; 3,33 em 105 pontos), entretanto, na avalia&#231;&#227;o com vari&#225;veis obtidas com o teste de caminhada, n&#227;o houve correla&#231;&#227;o. </p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gf01.jpg"/></fig>
    <p>A an&#225;lise pareada das caracter&#237;sticas analisadas antes e durante o teste de caminhada revelou uma diferen&#231;a significativa entre os indiv&#237;duos que foram a &#243;bito nos 12 meses subseq&#252;entes e o grupo sobrevivente, quanto a caracter&#237;sticas como peso, rela&#231;&#227;o C/Q (cintura/quadril), for&#231;a muscular respirat&#243;ria (P<sub>i-m&#225;x. e </sub>P<sub>i-m&#225;x.</sub>), EP (esfor&#231;o percebido) e a freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o no 2&#186; minuto (FCR<sub>2</sub>) (<xref ref-type="table" rid="a11tab04m">tab. 4</xref>). </p>
    <p content-type="asset">
      <table-wrap id="a11tab04m">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt04.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O presente estudo demonstrou que o TC6, sem acompanhamento, apresentou-se como medida segura quanto &#224;s altera&#231;&#245;es eletrocardiogr&#225;ficas e cardiovasculares, na avalia&#231;&#227;o de pacientes com insufici&#234;ncia card&#237;aca refrat&#225;ria, mas refor&#231;a a import&#226;ncia da avalia&#231;&#227;o cl&#237;nica e disfuncional preliminar para estratifica&#231;&#227;o de risco. Al&#233;m disso, algumas vari&#225;veis relacionadas ao desempenho no TC6 parecem de fato estar associadas com o estadiamento cl&#237;nico atual e com a ocorr&#234;ncia de mortalidade no seguimento de um ano. </p>
    <p>O TC6 tem se apresentado como um exame simples, reprodut&#237;vel, de baixo custo e reduzida dificuldade operacional, com importante correla&#231;&#227;o com vari&#225;veis cl&#237;nicas, como capacidade funcional, condicionamento cardiorrespirat&#243;rio, classe funcional, qualidade de vida e progn&#243;stico cardiovascular<sup>4,6,8-13,17,19-24</sup>. O presente estudo utilizou pioneiramente um sistema de monitora&#231;&#227;o eletrocardiogr&#225;fica por telemetria durante o TC6 em solo, permitindo assim a observa&#231;&#227;o em tempo real de poss&#237;veis arritmias ou sinais sugestivos de isquemia, que poderiam indicar a suspens&#227;o do teste. Al&#233;m disso, tamb&#233;m realizou an&#225;lise simplificada do lactato perif&#233;rico, a fim de inferir informa&#231;&#245;es agudas sobre modula&#231;&#245;es no metabolismo energ&#233;tico.</p>
    <p>Com hist&#243;rico comum de presen&#231;a de fatores de risco, procedimentos pr&#233;vios e comorbidades associadas, os indiv&#237;duos apresentaram importante redu&#231;&#227;o da fun&#231;&#227;o cardiovascular, concentrando-se predominantemente nas classes funcionais III e IV, e tendo como principal etiologia as doen&#231;as isqu&#234;micas do mioc&#225;rdio. Historicamente, um ter&#231;o dos pacientes internados com diagn&#243;stico de insufici&#234;ncia card&#237;aca gasta anualmente cerca de 11 bilh&#245;es em tratamento ambulatorial<sup>1</sup>, despesas que se concentram principalmente nos pacientes em classes funcionais III e IV. Assim, medidas simples, reprodut&#237;veis e eficientes para avalia&#231;&#227;o e suporte ao tratamento cardiovascular podem ser de extrema relev&#226;ncia, pois reduzem custos e oferecem um acompanhamento mais qualificado. A qualidade de vida que se apresentou neste estudo, apenas moderadamente reduzida e sem correla&#231;&#227;o com vari&#225;veis do TC6, j&#225; foi demonstrada em estudos preliminares, o que se deve provavelmente ao fato de termos avaliado um n&#250;mero restrito de pacientes nas diferentes classes funcionais<sup>10</sup>.</p>
    <p>A an&#225;lise da ocorr&#234;ncia de arritmias foi realizada de tr&#234;s formas: </p>
    <p>&#149; Classifica&#231;&#227;o proposta por Low e Wolf<sup>32</sup> que considera a gravidade das arritmias ventriculares.</p>
    <p>&#149; Classifica&#231;&#227;o atriovernticular (AV) que divide as arritmias em ventriculares e supraventriculares<sup>27</sup>. </p>
    <p>&#149; Avalia&#231;&#227;o qualitativa (descritiva) dos achados eletrocardiogr&#225;ficos<sup>26</sup>. </p>
    <p>As duas &#250;ltimas an&#225;lises relatam uma maior incid&#234;ncia de arritmias em pacientes com redu&#231;&#227;o no suprimento de oxig&#234;nio no mioc&#225;rdio. No presente estudo, a an&#225;lise evidenciou a alta probabilidade de ocorr&#234;ncia de arritmias nessa popula&#231;&#227;o, mas que n&#227;o foram exacerbadas ante o TC6, o que sugere a seguran&#231;a do m&#233;todo, mas enfatizando a necessidade de uma avalia&#231;&#227;o cl&#237;nica e disfuncional preliminar estratificadora. No entanto, o uso rotineiro de sistemas de monitora&#231;&#245;es eletrocardiogr&#225;ficas deve ser bem avaliado, uma vez que o teste de caminhada tem por princ&#237;pio ser um teste de simplificado e de f&#225;cil reprodutibilidade. </p>
    <p>Na an&#225;lise do ajuste cardiovascular ante o TC6, a FC foi a vari&#225;vel que demonstrou ajuste mais expressivo perante o teste. Tal comportamento traduz a influ&#234;ncia da vari&#225;vel nas varia&#231;&#245;es do duplo produto card&#237;aco, visto que estes j&#225; apresentam perda da fun&#231;&#227;o cardiovascular, evidenciada pela reduzida fra&#231;&#227;o de eje&#231;&#227;o ventricular. Dessa forma, assim como poder&#237;amos imaginar, a resposta cronotr&#243;pica foi mais importante do que a inotr&#243;pica nessa popula&#231;&#227;o<sup>15</sup>. A FCR<sub>2</sub> encontrava-se mais elevada no grupo que foi a &#243;bito nos 12 meses de seguimento. Alguns estudos t&#234;m descrito a rela&#231;&#227;o do comportamento da freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o (FCR) com a fun&#231;&#227;o cardiovascular, em que redu&#231;&#245;es mais lentas est&#227;o diretamente relacionadas com a piora da fun&#231;&#227;o e mortalidade cardiovascular, fen&#244;meno este ligado a um desbalan&#231;o do sistema nervoso auton&#244;mico, geralmente produzido por hiperestimula&#231;&#227;o do sistema nervoso simp&#225;tico e redu&#231;&#227;o da atividade vagal<sup>21,33</sup>, al&#233;m de mensurar mudan&#231;as na capacidade funcional ap&#243;s programa de condicionamento<sup>34</sup>. </p>
    <p>Al&#233;m disso, a avalia&#231;&#227;o simplificada do lactato foi capaz de estimar informa&#231;&#245;es adicionais quanto ao comportamento do metabolismo energ&#233;tico ante o teste de caminhada. Pudemos constatar que, apesar de a freq&#252;&#234;ncia card&#237;aca m&#225;xima (FC<sub>m&#225;x.</sub>) ter atingido em m&#233;dia apenas 66,3 % do previsto, quatro desses pacientes ultrapassaram o valor de 4 mmol/l na an&#225;lise do comportamento do lactato, sugerindo maior utiliza&#231;&#227;o de metabolismo anaer&#243;bio. Estudos recentes demonstram a rela&#231;&#227;o entre o metabolismo anaer&#243;bio e a capacidade funcional como importante preditor de mortalidade<sup>35,36</sup>. Ainda assim, ap&#243;s o TC6, os indiv&#237;duos relataram em esfor&#231;o percebido m&#233;dio de 14,3 &#177; 1,55 em 20 pontos, o que corresponde a um esfor&#231;o mais pr&#243;ximo de cansativo, resultado este compat&#237;vel com o esfor&#231;o relatado em outros estudos<sup>9</sup>. Esses achados nos permitem inferir um poss&#237;vel erro na estimativa da freq&#252;&#234;ncia card&#237;aca m&#225;xima para esses pacientes com importante limita&#231;&#227;o funcional e que, em sua maioria (83,3%), faziam uso de tratamento betabloqueador<sup>37,38</sup>. </p>
    <p>Como pudemos observar na avalia&#231;&#227;o cl&#237;nica inicial, as vari&#225;veis que mais se diferenciaram nos indiv&#237;duos que foram a &#243;bito nos 12 meses subseq&#252;entes em rela&#231;&#227;o aos que sobreviveram foram peso, for&#231;a muscular e rela&#231;&#227;o cintura/quadril. O peso e a for&#231;a muscular s&#227;o importantes marcadores nessa popula&#231;&#227;o, haja vista que, com a evolu&#231;&#227;o da insufici&#234;ncia card&#237;aca, estes desenvolvem aumento da demanda energ&#233;tica metab&#243;lica associada a uma percept&#237;vel degrada&#231;&#227;o musculoesquel&#233;tica, podendo gerar um est&#225;gio funcional denominado caquexia card&#237;aca, interferindo de forma negativa no condicionamento cardiorrespirat&#243;rio e conseq&#252;entemente na qualidade de vida e no progn&#243;stico cardiovascular<sup>2,3</sup>. </p>
    <p>J&#225; a an&#225;lise da rela&#231;&#227;o entre o TC6 e o estadiamento cl&#237;nico e progn&#243;stico cardiovascular revelou primariamente que, apesar de pertencerem a um grupo aparentemente homog&#234;neo, ambos igualmente j&#225; eleg&#237;veis para o transplante card&#237;aco, estes apresentavam uma capacidade funcional, estimada pela dist&#226;ncia percorrida, muito diversificada, principalmente para os quatro pacientes que percorreram uma dist&#226;ncia inferior a 300 metros. Sabe-se atualmente que os indiv&#237;duos com insufici&#234;ncia card&#237;aca que caminham menos que 300 metros t&#234;m um progn&#243;stico muito prejudicado<sup>14-16</sup>. Al&#233;m disso, em nosso estudo, a dist&#226;ncia m&#225;xima percorrida no TC6 demonstrou importante correla&#231;&#227;o com algumas caracter&#237;sticas cl&#237;nicas cl&#225;ssicas como a fra&#231;&#227;o de eje&#231;&#227;o (r = 0,70) e classe funcional (r = 0,73). Apesar de alguns estudos questionarem a utilidade do teste como medida de estadiamento cl&#237;nico cardiovascular, a maior parte dos ensaios cl&#237;nicos randomizados &#233; a favor do valor diagn&#243;stico nos pacientes com insufici&#234;ncia card&#237;aca<sup>10,15</sup>. </p>
    <p>Por fim, na compara&#231;&#227;o do grupo sobrevivente com os que foram a &#243;bito, pudemos observar que a rela&#231;&#227;o entre a dist&#226;ncia percorrida e o esfor&#231;o percebido (metros/EP), o esfor&#231;o percebido (EP) e a freq&#252;&#234;ncia card&#237;aca de recupera&#231;&#227;o (FCR, bpm) foram as vari&#225;veis que melhor se diferenciaram quando comparamos os indiv&#237;duos que foram a &#243;bito com os sobreviventes. </p>
    <p>O presente estudo apresentou algumas limita&#231;&#245;es. Inicialmente, avaliamos uma amostra relativamente pequena de pacientes com indica&#231;&#227;o eletiva para transplante card&#237;aco. No entanto, apesar de termos demonstrado resultados relevantes nesta pesquisa, ressaltamos a dificuldade no acesso a essa popula&#231;&#227;o, uma vez que, durante todo o per&#237;odo de realiza&#231;&#227;o do estudo, a Associa&#231;&#227;o Brasileira de Transplante de &#211;rg&#227;os (ABTO) contabilizou apenas 60 transplantes card&#237;acos no Estado de S&#227;o Paulo, para um total de 98 cadastrados<sup>39</sup>. Assim, a popula&#231;&#227;o avaliada correspondeu a um total de 12% do total de pacientes cadastrados, sinalizando a import&#226;ncia da proposi&#231;&#227;o de estudos multic&#234;ntricos no futuro. Al&#233;m disso, a an&#225;lise simplificada para compara&#231;&#227;o transversal em substitui&#231;&#227;o a uma an&#225;lise detalhada sobre a mortalidade tamb&#233;m se justificou pelo fato de dispormos de um n&#250;mero restrito pacientes. </p>
    <p>Em suma, o comportamento cl&#237;nico e eletrocardiogr&#225;fico sugere que o m&#233;todo &#233; seguro, mas pode ser considerado de alta intensidade para alguns pacientes com insufici&#234;ncia card&#237;aca grave. Vari&#225;veis relacionadas ao desempenho no TC6 podem estar associadas com a mortalidade no seguimento de um ano. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Gerson Cipriano Jr. pela Unifesp.</p>
    <p>
      <fn id="add1" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Gerson Cipriano Junior </p>
        <p> Rua Traituba, 227, ap. 113 - Sa&#250;de </p>
        <p> 04142-050 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="ciprianeft@uol.com.br">ciprianeft@uol.com.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 27/11/07; revisado recebido em 07/05/08; aceito em 02/07/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Mady C. Current situation of the treatment of heart failure in Brazil. Arq Bras Cardiol. 2007; 89 (4): e 84-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Current situation of the treatment of heart failure in Brazil</article-title>
          <source>Arq Bras Cardiol.</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>e 84</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mady</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999; 115 (3): 836-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation</article-title>
          <source>Chest</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>836</fpage>
          <lpage>47</lpage>
          <issue>3</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Juenger J, Schellberger D, Kraemer S, Haunstetter A, Zugek C, Herzog W, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002; 87 (3): 235-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables</article-title>
          <source>Heart</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>235</fpage>
          <lpage>41</lpage>
          <issue>3</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Juenger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schellberger</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kraemer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haunstetter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zugek</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Myers J, Geiran O, Simonsen S, Ghuyoiemi A, Gilles-Tad L. Clinical and exercise test determinants of survival after cardiac transplantation. Chest. 2003; 124 (5): 2000-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and exercise test determinants of survival after cardiac transplantation</article-title>
          <source>Chest</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2000</fpage>
          <lpage>5</lpage>
          <issue>5</issue>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Geiran</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Simonsen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ghuyoiemi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gilles-Tad</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Sociedade Brasileira de Cardiologia. I Guidelines of the Brazilian Cardiology Society for Heart Transplantation: IX. Organization of heart transplantation in Brazil. Arq Bras Cardiol. 1999; 73 (Suppl 5): 56-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Guidelines of the Brazilian Cardiology Society for Heart Transplantation: IX. Organization of heart transplantation in Brazil</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>56</fpage>
          <lpage>7</lpage>
          <volume>73</volume>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Bettencourt P, Ferreira A, Dias P, Pimenta J, Fri&#245;es F, Martins L, et al.  Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail. 2000; 6 (4): 306-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of prognosis in patients with stable mild to moderate heart failure</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>306</fpage>
          <lpage>13</lpage>
          <issue>4</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bettencourt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fri&#245;es</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Sociedade Brasileira de Cardiologia. II Guidelines on Ergometric Tests of the Brazilian Society of Cardiology. Arq Bras Cardiol. 2002; 78 (Suppl 2): 1-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>II Guidelines on Ergometric Tests of the Brazilian Society of Cardiology</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <volume>78</volume>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999; 14 (2): 270-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six minute walking distance in healthy elderly subjects</article-title>
          <source>Eur Respir J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>270</fpage>
          <lpage>4</lpage>
          <issue>2</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Troosters</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gosselink</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Decramer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Delahaye N, Cohen-Solal A, Faragi M, Czutrom D, Foult JM, Daou D, et al.  Comparison of left ventricular responses to the six-minute walk test, stair climbing, and maximal upright bicycle exercise in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1997; 80 (1): 65-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of left ventricular responses to the six-minute walk test, stair climbing, and maximal upright bicycle exercise in patients with congestive heart failure due to idiopathic dilated cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>65</fpage>
          <lpage>70</lpage>
          <issue>1</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Delahaye</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cohen-Solal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Faragi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Czutrom</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Foult</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Daou</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Demers C, McKelvie RS, Negassa A, Yusuf S, Resolvd Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. 2001; 142 (4): 698-703.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>698</fpage>
          <lpage>703</lpage>
          <issue>4</issue>
          <volume>142</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Demers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McKelvie</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Negassa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Kervio G, Ville NS, Leclerq C, Daubert JC, Carre F. Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients. Eur J Cardiovasc Prev Rehabil. 2004; 11 (2): 171-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiorespiratory adaptations during the six-minute walk test in chronic heart failure patients</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>171</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kervio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ville</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Leclerq</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Daubert</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Carre</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J. 2005; 26 (8): 778-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>778</fpage>
          <lpage>93</lpage>
          <issue>8</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Olsson</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Witte</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Rubim VS, Drumond Neto C, Romeo JL, Monteiro MW. Prognostic value of the six-minute walk test in heart failure. Arq Bras Cardiol. 2006; 86 (2): 120-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of the six-minute walk test in heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>120</fpage>
          <lpage>5</lpage>
          <issue>2</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rubim</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Drumond Neto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Romeo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Monteiro</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Bittner V. Determining prognosis in congestive heart failure: role of the 6-minute walk test. Am Heart J. 1999; 138 (4 Pt 1): 593-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determining prognosis in congestive heart failure: role of the 6-minute walk test</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>593</fpage>
          <lpage>6</lpage>
          <issue>4 Pt 1</issue>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bittner</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Rostagno C, Olivo G, Comeglio M, Boddi V, Bauchelli M, Galanti G, et al. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail. 2003; 5 (3): 247-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>247</fpage>
          <lpage>52</lpage>
          <issue>3</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rostagno</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Olivo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Comeglio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boddi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bauchelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Galanti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J. 1998; 136 (3): 449-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>449</fpage>
          <lpage>57</lpage>
          <issue>3</issue>
          <volume>136</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roul</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Germain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bareiss</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Hegbom F, Stavem K, Sire S, Heldal M, Clrming OM, Gjesdal K.  Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation. Int J Cardiol. 2007; 116 (1): 86-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>86</fpage>
          <lpage>92</lpage>
          <issue>1</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hegbom</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stavem</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sire</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Heldal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clrming</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Gjesdal</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992; 124 (4): 1017-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1017</fpage>
          <lpage>25</lpage>
          <issue>4</issue>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Cahalin LP, Mathier MA, Lemigran MJ, Dec GW, De Salvo JG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996; 110 (2): 325-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>325</fpage>
          <lpage>32</lpage>
          <issue>2</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cahalin</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Mathier</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lemigran</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Dec</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>De Salvo</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Lucas C, Stevenson LW, Johnson W, Hartley H, Hamilton MA, Walden J, et al.  The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999; 138 (4 Pt 1): 618-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>618</fpage>
          <lpage>24</lpage>
          <issue>4 Pt 1</issue>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lucas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Walden</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Meyer K, Schwarbold M, Westbrook S, Beneke R, Hajric R, Lehmann M, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. Am Heart J. 1997; 133 (4):  447-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>447</fpage>
          <lpage>53</lpage>
          <issue>4</issue>
          <volume>133</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schwarbold</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Westbrook</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beneke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hajric</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Witham MD, McMurdo ME. Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials. Am Heart J. 2003; 146 (2): E7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>E7</fpage>
          <issue>2</issue>
          <volume>146</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Witham</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>McMurdo</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Zugck C, Kriiger C, D&#252;rr S, Gerber SH, Haunstetter A, Hemig K, et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J. 2000; 21 (7): 540-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy?</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>540</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zugck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kriiger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>D&#252;rr</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerber</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Haunstetter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hemig</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Araujo CO, Makdisse MR, Peres PA, Tebexreni AS, Ramos LR, Matsushita AM, et al. Different patterns for the 6-minute walk test as a test to measure exercise ability in elderly with and without clinically evident cardiopathy. Arq Bras Cardiol. 2006; 86 (3): 198-205.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Different patterns for the 6-minute walk test as a test to measure exercise ability in elderly with and without clinically evident cardiopathy</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <issue>3</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Araujo</surname>
              <given-names>CO</given-names>
            </name>
            <name>
              <surname>Makdisse</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Peres</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Tebexreni</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Matsushita</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Hambrecht R, Adams V, Gielen S, Linke A, Wendlers S, Yu J, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999; 33 (1): 174-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>174</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hambrecht</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gielen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Linke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wendlers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Belardinelli R. Arrhythmias during acute and chronic exercise in chronic heart failure. Int J Cardiol. 2003; 90 (2-3): 213-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Arrhythmias during acute and chronic exercise in chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>213</fpage>
          <lpage>8</lpage>
          <issue>2-3</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Belardinelli</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Galante A, Pietrowist A, Cavazzini C, Magrini A, Bergamaschi A, Sciarra L, et al. Incidence and risk factors associated with cardiac arrhythmias during rehabilitation after coronary artery bypass surgery. Arch Phys Med Rehabil. 2000; 81 (7): 947-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Incidence and risk factors associated with cardiac arrhythmias during rehabilitation after coronary artery bypass surgery</article-title>
          <source>Arch Phys Med Rehabil</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>947</fpage>
          <lpage>52</lpage>
          <issue>7</issue>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Galante</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pietrowist</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavazzini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Magrini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bergamaschi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sciarra</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Fisher JD. New York Heart Association Classification. Arch Intern Med. 1972; 129 (5): 836.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New York Heart Association Classification</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>1972</year>
          </date>
          <fpage>836</fpage>
          <issue>5</issue>
          <volume>129</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. AACVPR Guidelines for cardiac rehabilitation and secondary prevention programs. 4th ed. Champaing: Human Kinetics; 2004.</mixed-citation>
        <element-citation publication-type="book">
          <source>Guidelines for cardiac rehabilitation and secondary prevention programs</source>
          <date>
            <year>2004</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14 (5): 377-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychophysical bases of perceived exertion</article-title>
          <source>Med Sci Sports Exerc</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>377</fpage>
          <lpage>81</lpage>
          <issue>5</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borg</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Guimaraes GV, Bellotti G, Bacal F, Mocelin A, Bocchi EA. Can the cardiopulmonary 6-minute walk test reproduce the usual activities of patients with heart failure? Arq Bras Cardiol. 2002; 78 (6): 553-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Can the cardiopulmonary 6-minute walk test reproduce the usual activities of patients with heart failure?</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>553</fpage>
          <lpage>60</lpage>
          <issue>6</issue>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimaraes</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mocelin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971; 44 (1): 130-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Approaches to sudden death from coronary heart disease</article-title>
          <source>Circulation</source>
          <date>
            <year>1971</year>
          </date>
          <fpage>130</fpage>
          <lpage>42</lpage>
          <issue>1</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lown</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Kligfield P, McCormick A, Chai A, Jacobson A, Feurstadt P, Hao SC. Effect of age and gender on heart rate recovery after submaximal exercise during cardiac rehabilitation in patients with angina pectoris, recent acute myocardial infarction, or coronary bypass surgery. Am J Cardiol. 2003; 92 (5): 600-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of age and gender on heart rate recovery after submaximal exercise during cardiac rehabilitation in patients with angina pectoris, recent acute myocardial infarction, or coronary bypass surgery</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>600</fpage>
          <lpage>3</lpage>
          <issue>5</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feurstadt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Myers J, Hadley D, Oswald U, Bruner K, Kottnan W, Hsu L, et al. Effects of exercise training on heart rate recovery in patients with chronic heart failure. Am Heart J. 2007; 153 (6): 1056-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of exercise training on heart rate recovery in patients with chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1056</fpage>
          <lpage>63</lpage>
          <issue>6</issue>
          <volume>153</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hadley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Oswald</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bruner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kottnan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007; 115 (18): 2410-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Development of a ventilatory classification system in patients with heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2410</fpage>
          <lpage>7</lpage>
          <issue>18</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Abella</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Peberdy</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bensimhon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chase</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady GJ, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation. 2007; 116 (3): 329-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>329</fpage>
          <lpage>43</lpage>
          <issue>3</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gulati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kligfield</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Heck H, Mader A, Hess G, M&#252;cke S, M&#252;ller R, Hollmann W. Justification of the 4-mmol/l lactate threshold. Int J Sports Med. 1985; 6 (3): 117-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Justification of the 4-mmol/l lactate threshold</article-title>
          <source>Int J Sports Med</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>117</fpage>
          <lpage>30</lpage>
          <issue>3</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heck</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mader</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>M&#252;cke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>M&#252;ller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hollmann</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Wasserman K. The anaerobic threshold measurement in exercise testing. Clin Chest Med. 1984; 5 (1): 77-88.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The anaerobic threshold measurement in exercise testing</article-title>
          <source>Clin Chest Med</source>
          <date>
            <year>1984</year>
          </date>
          <fpage>77</fpage>
          <lpage>88</lpage>
          <issue>1</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wasserman</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Associa&#231;&#227;o Brasileira de Transplante de Org&#227;os (ABTO). Registro Brasileiro de Transplantes. 2006; 12 (2): 5-6.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Registro Brasileiro de Transplantes.</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>5</fpage>
          <lpage>6</lpage>
          <issue>2</issue>
          <volume>12</volume>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Analysis of 6-minute walk test safety in pre-heart transplantation patients</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The 6-minute walk test (6WT) has been used as a means of assessment of the functional capacity, clinical staging and cardiovascular prognosis. Its safety and metabolic impact have not been frequently described in the literature, especially in patients with severe heart failure with clinical indication for cardiovascular transplantation. OBJECTIVE: To evaluate the occurrence of arrhythmias and cardiovascular changes during 6WT. To correlate 6WT performance with clinical staging and cardiovascular prognosis. METHODS: Twelve patients, 10 of whom males, aged 52 &#177; 8 years were evaluated at baseline. 6WT was performed with telemetry electrocardiography, vital signs and lactate monitoring. The patients were followed-up for 12 months. RESULTS: The patients walked 399.4&#177;122.5 (D, m), reaching a perceived exertion (PE) of 14.3&#177;1.5 and a 34% baseline heart rate variation. Two patients presented more severe pre-6WT arrhythmia which did not worsen with the exercice, four patients presented a significant increase of blood lactate levels (&gt;5 mmol/dl), and three interrupted the test. The distance walked correlated with the ejection fraction (%) and functional class (NYHA). After 12-month follow-up, three patients died and seven were rehospitalized for cardiac decompensation. The D/PE ratio and 2-minute heart rate recovery (HRR2, bpm) were lower in the death group. CONCLUSION: The clinical and electrocardiographic behaviors suggest that the method is safe, but it may be considered too strenuous for some patients with severe heart failure. Variables related to 6WT performance may be associated with the one-year follow-up mortality.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Walking</kwd>
        <kwd>health evaluation</kwd>
        <kwd>effectiveness</kwd>
        <kwd>heart failure</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="topo-body2"/>Analysis of 6-minute walk test safety in pre-heart transplantation patients</p>
      <p>
        <bold>Gerson Cipriano Jr; Darlene Yuri, Graziella Fran&#231;a Bernardelli; Vanessa Mair; Enio Buffolo; Jo&#227;o Nelson Rodrigues Branco</bold>
      </p>
      <p>Universidade Federal de S&#227;o Paulo, Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> The 6-minute walk test (6WT) has been used as a means of assessment of the functional capacity, clinical staging and cardiovascular prognosis. Its safety and metabolic impact have not been frequently described in the literature, especially in patients with severe heart failure with clinical indication for cardiovascular transplantation.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the occurrence of arrhythmias and cardiovascular changes during 6WT. To correlate 6WT performance with clinical staging and cardiovascular prognosis.</p>
      <p><bold>METHODS:</bold> Twelve patients, 10 of whom males, aged 52&#177;8 years were evaluated at baseline. 6WT was performed with telemetry electrocardiography, vital signs and lactate monitoring. The patients were followed-up for 12 months.</p>
      <p><bold>RESULTS:</bold> The patients walked 399.4&#177;122.5 (D, m), reaching a perceived exertion (PE) of 14.3&#177;1.5 and a 34% baseline heart rate variation. Two patients presented more severe pre-6WT arrhythmia which did not worsen with the exercice, four patients presented a significant increase of blood lactate levels (&gt;5 mmol/dl), and three interrupted the test. The distance walked correlated with the ejection fraction (%) and functional class (NYHA). After 12-month follow-up, three patients died and seven were rehospitalized for cardiac decompensation. The D/PE ratio and 2-minute heart rate recovery (HRR2, bpm) were lower in the death group.</p>
      <p><bold>CONCLUSION:</bold> The clinical and electrocardiographic behaviors suggest that the method is safe, but it may be considered too strenuous for some patients with severe heart failure. Variables related to 6WT performance may be associated with the one-year follow-up mortality. (Arq Bras Cardiol 2009;92(4):294-300)</p>
      <p><bold>Key words:</bold> Walking; health evaluation; effectiveness; heart failure.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Refractory heart failure is an end-stage condition in several heart diseases and is characterized by deterioration of the clinical conditions and mortality<sup>1</sup>. Failure of compensatory mechanisms for maintenance of the cardiac output facilitates protein-energy malnutrition and reduction of the vascular bed and functional capacity<sup>2,3</sup>. Heart transplantation has been an efficient therapeutic option, improving survival and functional capacity (FC). However, after clinical indication, the therapeutical follow-up in the pre-transplantation phase is delicate and costly<sup>4,5</sup>.</p>
      <p>Cardiopulmonary evaluation is the most accurate method in the assessment and follow-up of the functional capacity. However, it is difficult to be performed periodically, and this may impair a more detailed control of patients with this clinical condition<sup>6,7</sup>. In these cases, the 6-minute walk test (6WT) may be indicated as an alternative simplified low-cost reproducible method<sup>8</sup>, for the assessment of exercice tolerance, providing an indirect estimate of different aspects such as clinical staging<sup>9-16</sup>, response to interventions, and quality of life<sup>17,18</sup>, especially in patients with a greater reduction of the functional capacity<sup>19-24</sup>. </p>
      <p>The more specific scientific knowledge regarding safety and major systemic adjustments in response to 6WT in patients with refractory heart failure (HF) could minimize the occurrence of adverse clinical responses<sup>25</sup> such as signs of exercice intolerance, arrhythmias, and secondary complications, especially found when reduced myocardial oxygen supply is present, which is very frequent among this population<sup>26,27</sup>.</p>
      <p>The objective of the present study is to evaluate the cardiovascular responses to 6WT and their possible correlations with clinical staging and cardiovascular prognosis. Thereby we believe we will contribute to the improvement of intervention control and prescription in this population of heart disease patients who await heart transplantation.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study participants</bold>
      </p>
      <p>Twelve patients (aged 52 &#177; 8 years, 10 men, 2 women) seen in the heart transplantation outpatient clinic of the university hospital of <italic>Universidade Federal de S&#227;o Paulo </italic>comprised the study group. The patients were clinically diagnosed with refractory heart failure with elective indication for heart transplantation. The main causes of heart failure were related to ischemic (58.3%) and idiopathic (25%) cardiomyopathies. Eight patients (67.7%) were in functional class III and IV (NYHA), 10 (83.3%) had associated comorbidities, and nine (75%) had already undergone previous cardiovascular procedures (five coronary artery bypass graftings and four transluminal angioplasties) (<xref ref-type="table" rid="tab1-body2">Table 1</xref>). Consent was obtained from all patients, and the study was approved by the Research Ethics Committee.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Design and protocol</bold>
      </p>
      <p>This was a prospective cohort of 15 patients, of whom three were excluded for cardiovascular decompensation; therefore 12 remained in the protocol. The study comprised a baseline clinical assessment with information on clinical and cardiovascular staging, followed by a 6-minute walk test (6WT). The patients were then clinically followed-up for 12 months after 6WT.</p>
      <p>
        <bold>Baseline clinical assessment</bold>
      </p>
      <p>The baseline clinical assessment included information on the clinical and echocardiographic evaluations, such as etiology, presence of comorbidities, previous cardiovascular procedures, clinical treatment, cardiovascular function (% ejection fraction) and functional class (NYHA)<sup>28</sup>. The patients were also evaluated as to the impact of heart failure on their quality of life, by means of a specific questionnaire for heart failure known as Minnesota Living with Heart Failure questionnaire (MLHF)<sup>18</sup>. </p>
      <p>
        <bold>6-minute walk test</bold>
      </p>
      <p>Rest electrocardiogram was initially obtained from the patients in order to detect the existence of arrhythmias. The 6WT was performed according to the Guidelines of the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)<sup>29</sup> and guidelines for the performance of exercice tests of the Brazilian Society of Cardiology (SBC)<sup>7</sup>, in a 30-m-long circular track with the patients unaccompanied and receiving only standardized advices every minute. The following parameters were monitored: heart rate (HR, bpm), heart rate recovery (HRR, bpm), blood pressure (BP, mmHg), peripheral oxygen saturation (SpO<sub>2</sub>, %) and perceived exertion (PE) scale<sup>30</sup>. Continuous telemetry electrocardiography (QUARK T12, model CO9055-32-99, Cosmed<sup>TM</sup>, Italy) was also performed and allowed instant monitorization of events that could indicate the need for test interruption. Also, peripheral lactate values before and after 6WT were determined. The baseline peripheral measurement was determined after a minimum one-hour period without the performance of exercices and/or exertion activities, and the final measurement was determined right after the end of the test.</p>
      <p>
        <bold>12-month post-6WT follow-up</bold>
      </p>
      <p>The patients were followed-up for a 12-month period after 6WT so that parameters regarding the clinical outcome such as rehospitalization, decompensation of the clinical manifestations and mortality could be observed.</p>
      <p>
        <bold>Statistical methods</bold>
      </p>
      <p>Continuous parametric data were expressed as mean and standard deviation and compared throughout time using ANOVA for repeated measurements with Newman-Keuls post-test for more than two timepoints or, otherwise, with Sudent's t test. Non-parametric data were expressed as median and percentile and compared throughout time using Friedman's test with Muller-Dunn post-test for more than two timepoints or, otherwise, with Wilcoxon's test. Categorical data were expressed as absolute frequency (n) and relative frequency (%) and compared throughout time using Mc'Nemar's test, or the chi-square test for independent groups. Pearson's linear correlation analysis was used to verify the association between the test variables with clinical and cardiovascular staging, with values set at &gt; 0.75, &lt;0.40, and between 0.40 and 0.75 for excellent, poor and moderate concordance, respectively. For the entire study, the alpha risk was set at equal to or lower than 5%, and beta risk at equal to or lower than 20%. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Occurrence of arrhythmias</bold>
      </p>
      <p>The occurrence of arrhythmia was evaluated in three ways during 6WT. The descriptive analysis, represented by the type of arrhythmia, did not show exacerbation with 6WT (p=0.228). Qualitative analysis regarding change in risk stratification during the test did not show exacerbation either, and classifications were used regarding the origin (p=0.546) or type (p=0.735) (<xref ref-type="table" rid="en_a11tab02-body2">Table 2</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_a11tab02-body2">
          <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt02-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Maximum performance in 6WT</bold>
      </p>
      <p>Unlike SpO<sub>2</sub> and BP, which did not change significantly with exercice, HR adjusted efficiently and physiologically, and was the major responsible for the positive adjustment of the double product (<xref ref-type="table" rid="tab3-body2">Table 3</xref>).</p>
      <table-wrap id="tab3-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt03-en.jpg"/></table-wrap>
      <p>The mean distance walked was 399.4 &#177; 122.5, with significant increase in the perceived exertion (14 &#177; 1.5)<sup>31</sup> and evident variation in lactate levels. Greater than 4mmol/L lactate levels were reached in four individuals, thus suggesting higher utilization of anaerobic metabolism during the exercise. Other three individuals interrupted the test early, the first one due to dyspnea, dizziness, palpitation, and leg pain at 285 seconds; the second due to leg pain at 242 seconds; and the third due to chest pain at 180 seconds, both with no electrocardiographic changes characteristic of ischemia (<xref ref-type="table" rid="tab3-body2">Table 3</xref>). After interruption, the patients could continue the test so as to complete the 360 seconds planned, and only then the total distance walked was calculated. </p>
      <p>
        <bold>Clinical staging and cardiovascular prognosis</bold>
      </p>
      <p>Three patients died within the 12-month follow-up period, two of them after rehospitalization for cardiovascular decompensation while awaiting cardiovascular transplantation, and one of late rejection following cardiovascular transplantation. Conventional periodic outpatient clinical follow-up was carried out, but only two patients underwent transplantation during the follow-up period, and the mean waiting time was 21.5 &#177; 4.95 months. Within this period, six (50%) patients had episodes of deterioration of the clinical staging and required hospitalization, five (41.67%) of them for heart failure decompensation and one (8.33%) for renal failure. </p>
      <p>The analysis of correlation of all variables obtained in 6WT showed association only between the distance walked and severity of arrhythmia at the end of 6WT, with EF (Ejection fraction) (R: 0.7 and -0.83) and FC (Functional class) (R: 0.73 and 0.73) (<xref ref-type="fig" rid="fig1-body2">Figure 1</xref>). Quality of life was moderately reduced (31 &#177; 3.33 out of 105 points); however, no correlation was demonstrated in the comparison with the variables obtained in the walk test. </p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gf01-en.jpg"/></fig>
      <p>Paired analysis of the characteristics studied before and during the walk test showed a significant difference between individuals who died within the 12 subsequent months and the group of survivors in relation to characteristics such as weight, waist/hip ratio, respiratory muscle strength (P<sub>i-max </sub><sub>and </sub>P<sub>e-max</sub>) ,PE (Perceived Exertion), and 2-minute heart rate recovery (<xref ref-type="table" rid="en_a11tab04-body2">Table 4</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_a11tab04-body2">
          <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt04-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The present study showed that unaccompanied 6WT is a safe measurement regarding the electrocardiografic and cardiovascular changes in the assessment of patients with refractory heart failure, but underscores the importance of preliminary clinical and functional assessment for risk stratification. Additionally, some variables related to 6WT performance seem to be indeed associated with the current clinical staging and with one-year follow-up mortality.</p>
      <p>6WT is a simple, reproducible, low-cost, easy-to-operate test that has a significant correlation with clinical variables such as functional capacity, cardiorespiratory conditioning, functional class, quality of life, and cardiovascular prognosis<sup>4,6,8-13,17,19-24</sup>. The present study was the first to use a telemetry electrocardiographic monitoring system during 6WT on the floor, thus permitting real-time observation of possible arrhythmias or signs suggestive of ischemia that could indicate the need for test interruption. Additionally, a simplified analysis of peripheral lactate was also carried out in order to obtain acute information on modulations of the energy metabolism.</p>
      <p>The individuals had a common history of presence of risk factors, previous procedures and associated comorbidities, as well as a significant reduction of the cardiovascular function, and were concentrated mainly in functional classes III and IV, whose main cause was myocardial ischemic diseases. Historically, one third of hospitalized patients diagnosed with heart failure spend approximately 55 billion US dollars anually in ambulatory treatment<sup>1</sup>, and these expenses concentrate mainly in functional class III and IV patients. Thus, simple, reproducible and efficient measures for the assessment of and support to cardiovascular treatment seem very relevant and could minimize these costs and provide a more qualified follow-up. Quality of life was only moderately reduced in this study, and did not correlate with 6WT variables, unlike what was demonstrated in other studies. This is probably due to the fact that we evaluated only a small number of patients in different functional classes<sup>10</sup>.</p>
      <p>The analysis of the occurrence of arrhythmias was carried out in three ways: using the classification proposed by Low<sup>32</sup>, which considers the severity of ventricular arrhythmias; the atrioventricular (AV) classification, which divides arrhythmias into ventricular and supraventricular arrhythmias<sup>27</sup>; and qualitative (descriptive) analysis of the electrocardiographic findings<sup>26</sup>. Both show a higher incidence of arrhythmias in patients with reduced myocardial oxygen supply. In the present study, the analysis showed a high probability of the occurrence of arrhythmias in this population, though without exacerbation with 6WT. This suggests that the method is safe, but we emphasize the need for a preliminary clinical and functional assessment for stratification. However, the routine use of electrocardiographic monitoring systems should be carefully considered, since the principle of the walk test is to be simple and easy to reproduce.</p>
      <p>In the analysis of the cardiovascular adjustment to 6WT, HR was the variable that showed the most significant adjustment to 6WT. This behavior is translated into the influence of HR on the double product variations, since these patients already present a diminished cardiovascular function, which is evidenced by a reduced ventricular ejection fraction. Thus, as we had expected, the chronotropic response was more important than the inotropic response in this population<sup>15</sup>. HRR2 was higher in the group of patients who died within the 12-month follow-up period. Some studies have described the relationship of the heart rate recovery (HRR) behavior with cardiovascular function, where slower reductions are directly related to function deterioration and cardiovascular mortality, a phenomenon that is linked to an autonomic nervous system imbalance, usually resulting from overstimulation of the sympathetic nervous system and reduction of the vagal activity<sup>21,33</sup>, in addition to measuring functional capacity changes after exercise training<sup>34</sup>.</p>
      <p>Also, the simplified lactate assessment permitted the supply of additional information regarding the energy metabolism behavior in response to the walk test. We could observe that although the maximum heart rate (HR<sub>max</sub>) had reached only 66.3% of the predicted value, on average, four of these patients had higher than 4mmol/l levels of lactate, thus suggesting greater utilization of anaerobic metabolism. Recent studies demonstrated the relationship between anaerobic metabolism and functional capacity as an important predictor of mortality<sup>35,36</sup>. Even so, after 6WT, the individuals reported a mean perceived exertion of 14.3 &#177; 1.55, with 20 points corresponding to a closer to tiresome exertion, a result that is compatible with the exertion reported in other studies<sup>9</sup>. Based on these findings we can presume a possible error in the estimate of the maximum heart rate for these patients with significant functional limitation who, in their majority (83.3%), were being treated with beta-blockers<sup>37,38</sup>.</p>
      <p>As we could observe, in the baseline clinical evaluation, the variables showing the most significant differences in the individuals who died in the 12 subsequent months in relation to those who survived were weight, muscle strength, and waist/hip ratio. Weight and muscle strength are important markers in this population, since with the progression of heart failure the patients develop an increased metabolic energy demand associated with a noticeable muscle-skeletal deterioration, which can lead to a functional stage known as cardiac cachexia that negatively interferes with the cardiorespiratory conditioning and, consequently, with the quality of life and cardiovascular prognosis<sup>2,3</sup>.</p>
      <p>The analysis of the relationship between 6WT and the clinical staging and cardiovascular prognosis, in turn, primarily revealed that despite belonging to an apparently homogeneous group, all being equally eligible to heart transplantation, the patients presented very different functional capacities, as estimated by the distance walked, especially the four patients who walked a shorter than 300-m distance. We currently know that individuals with heart failure who walk less than 300 meters have a very poor prognosis<sup>14-16</sup>. Also, in our study, the maximum distance walked in the 6WT showed an important correlation with some classical clinical characteristics such as ejection fraction (r=0.70) and functional class (r=0.73). Although some studies question the usefulness of this test as a measure of cardiovascular clinical staging, most of the randomized clinical trials support its diagnostic value in patients with heart failure<sup>10,15</sup>. </p>
      <p>Finally, in the comparison between the survivor group and the death group, we could observe that the distance walked and the perceived exertion ratio (meters/PE), perceived exertion (PE) and heart rate recovery (HRR, bpm) were the variables that showed the most significant differences when individuals who died were compared with the survivors.</p>
      <p>The present study had some limitations. Initially, we evaluated a relatively small sample of patients with elective indication for a heart transplant. However, although relevant results were shown in this study, we point out the difficulty in reaching this population, since during the entire study period the Brazilian Association of Organ Transplant (<italic>Associa&#231;&#227;o Brasileira de Transplante de &#211;rg&#227;os </italic>- ABTO), registered only 60 heart transplantations in the State of S&#227;o Paulo, for a total of 98 individuals enrolled<sup>39</sup>. Thus, the population assessed accounted for 12% of the total number of patients enrolled, which shows the importance of further multicenter studies. And the simplified analysis for cross-sectional comparison in place of a detailed analysis on mortality was also justified by the fact that we had a small number of patients, which led to a less affirmative degree of inference, though relevant for reassessment in prospective studies.</p>
      <p>In conclusion, the clinical and electrocardiographic behaviors suggest that the method is safe but can be considered strenuous for some patients with severe heart failure. Variables related to the performance in 6WT may be associated with the one-year follow-up mortality.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Gerion Cipriano Jr, from Unifesp.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Evaluaci&#243;n de la seguridad de la test de marcha de 6 minutos en pacientes en el pre-transplante cardiaco</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El test de marcha de 6 minutos (TM6m) ha sido utilizado como forma de evaluaci&#243;n de la capacidad funcional, del estadiamiento cl&#237;nico y el pron&#243;stico cardiovascular. La seguridad y el impacto metab&#243;lico son poco descritos en la literatura, principalmente en pacientes con insuficiencia cardiaca severa e indicaci&#243;n cl&#237;nica para transplante cardiovascular Objetivo: Evaluar la ocurrencia de arritmias y alteraciones cardiovasculares durante el TM6m. Correlacionar el desempe&#241;o en el TM6m con el estadiamiento cl&#237;nico y el pron&#243;stico cardiovascular. M&#201;TODOS: Un total de 12 pacientes, 10 varones, con edad de 52 &#177; 8 a&#241;os, fueron sometidos a evaluaci&#243;n inicial. Realizaron el TM6m con monitoreo electrocardiogr&#225;fico por telemetr&#237;a, se&#241;ales vitales y lactato. Se siguieron a los individuos por 12 meses. RESULTADOS: Los pacientes recorrieron 399,4 &#177; 122,5 (D, m), alcanzando un esfuerzo percibido (EP) de 14,3 &#177; 1,5 y variaci&#243;n del 34% en la frecuencia cardiaca basal. Dos pacientes presentaron arritmia de mayor severidad pre-TM6m y no mostraron empeoramiento ante el esfuerzo; cuatro tuvieron elevaci&#243;n significativa en los niveles de lactato sangu&#237;neo (&gt;5 mmol/dl), y tres interrumpieron el examen. La distancia recorrida evidenci&#243; correlaci&#243;n con la fracci&#243;n de eyecci&#243;n (%) y la clasificaci&#243;n funcional (NYHA). Tras 12 meses de seguimiento, tres pacientes murieron, y siete se reinternaron por descompensaci&#243;n cardiaca. La relaci&#243;n (D/EP) y frecuencia cardiaca de recuperaci&#243;n en el segundo minuto (FCR2, lpm) fueron inferiores en el grupo &#243;bito. CONCLUSI&#211;N: El comportamiento cl&#237;nico y electrocardiogr&#225;fico sugiere que el m&#233;todo es seguro, pero se puede considerarlo de alta intensidad para algunos pacientes con insuficiencia cardiaca severa. Variables relacionadas al desempe&#241;o en el TM6m pueden estar asociadas con la mortalidad en el seguimiento de un a&#241;o.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Marcha</kwd>
        <kwd>evaluaci&#243;n en salud</kwd>
        <kwd>efectividad</kwd>
        <kwd>insuficiencia cardiaca</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="add1-body3"/>Evaluaci&#243;n de la seguridad de la test de marcha de 6 minutos en pacientes en el pre-transplante cardiaco</p>
      <p>
        <bold>Gerson Cipriano Jr; Darlene Yuri; Graziella Fran&#231;a Bernardelli; Vanessa Mair; Enio Buffolo; Jo&#227;o Nelson Rodrigues Branco </bold>
      </p>
      <p>Universidade Federal de S&#227;o Paulo, Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> El test de marcha de 6 minutos (TM6m) ha sido utilizado como forma de evaluaci&#243;n de la capacidad funcional, del estadiamiento cl&#237;nico y el pron&#243;stico cardiovascular. La seguridad y el impacto metab&#243;lico son poco descritos en la literatura, principalmente en pacientes con insuficiencia cardiaca severa e indicaci&#243;n cl&#237;nica para transplante cardiovascular</p>
      <p><bold>OBJETIVO:</bold> Evaluar la ocurrencia de arritmias y alteraciones cardiovasculares durante el TM6m. Correlacionar el desempe&#241;o en el TM6m con el estadiamiento cl&#237;nico y el pron&#243;stico cardiovascular.</p>
      <p><bold>M&#201;TODOS:</bold> Un total de 12 pacientes, 10 varones, con edad de 52 &#177; 8 a&#241;os, fueron sometidos a evaluaci&#243;n inicial. Realizaron el TM6m con monitoreo electrocardiogr&#225;fico por telemetr&#237;a, se&#241;ales vitales y lactato. Se siguieron a los individuos por 12 meses. </p>
      <p><bold>RESULTADOS:</bold> Los pacientes recorrieron 399,4 &#177; 122,5 (D, m), alcanzando un esfuerzo percibido (EP) de 14,3 &#177; 1,5 y variaci&#243;n del 34% en la frecuencia cardiaca basal. Dos pacientes presentaron arritmia de mayor severidad pre-TM6m y no mostraron empeoramiento ante el esfuerzo; cuatro tuvieron elevaci&#243;n significativa en los niveles de lactato sangu&#237;neo (&gt;5 mmol/dl), y tres interrumpieron el examen. La distancia recorrida evidenci&#243; correlaci&#243;n con la fracci&#243;n de eyecci&#243;n (%) y la clasificaci&#243;n funcional (NYHA). Tras 12 meses de seguimiento, tres pacientes murieron, y siete se reinternaron por descompensaci&#243;n cardiaca. La relaci&#243;n (D/EP) y frecuencia cardiaca de recuperaci&#243;n en el segundo minuto (FCR2, lpm) fueron inferiores en el grupo &#243;bito.</p>
      <p><bold>CONCLUSI&#211;N:</bold> El comportamiento cl&#237;nico y electrocardiogr&#225;fico sugiere que el m&#233;todo es seguro, pero se puede considerarlo de alta intensidad para algunos pacientes con insuficiencia cardiaca severa. Variables relacionadas al desempe&#241;o en el TM6m pueden estar asociadas con la mortalidad en el seguimiento de un a&#241;o. (Arq Bras Cardiol 2009;92(4):303-309)</p>
      <p><bold>Palabras-clave:</bold> Marcha / caminata, evaluaci&#243;n en salud, efectividad, insuficiencia cardiaca.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca refractaria es condici&#243;n terminal de diversas cardiopat&#237;as, caracterizada por empeoramiento del cuadro cl&#237;nico y la mortalidad<sup>1</sup>. La falla de mecanismos compensatorios para el mantenimiento de gasto cardiaco favorece la desnutrici&#243;n energ&#233;tico-proteica y la reducci&#243;n del lecho vascular y de la capacidad funcional<sup>2,3</sup>. El transplante cardiaco ha sido una opci&#243;n terap&#233;utica eficiente, mejorando la sobrevida y la capacidad funcional (CF), sin embargo, tras indicaci&#243;n cl&#237;nica, el seguimiento terap&#233;utico en la fase pre-transplante es delicado y oneroso<sup>4,5</sup>. </p>
      <p>La evaluaci&#243;n cardiopulmonar es el m&#233;todo de mayor exactitud en la evaluaci&#243;n y en el seguimiento de la capacidad funcional. Sin embargo, su realizaci&#243;n peri&#243;dica es de dif&#237;cil ejecuci&#243;n, lo que puede dificultar un control m&#225;s detallado de los pacientes en esa condici&#243;n cl&#237;nica<sup>6,7</sup>. En esos casos, se puede indicar el test de marcha de 6 minutos (TM6m) como m&#233;todo alternativo simplificado, reproductible y de bajo costo<sup>8</sup>, para evaluaci&#243;n de la tolerancia al ejercicio. La elecci&#243;n del TM6m suministra una estimativa indirecta en cuanto a diversos aspectos -como estadiamiento cl&#237;nico<sup>9-16</sup>, respuesta a intervenciones y calidad de vida<sup>17,18</sup>- sobre todo en aquellos con mayor reducci&#243;n de la capacidad funcional<sup>19-24</sup>. </p>
      <p>El conocimiento cient&#237;fico m&#225;s espec&#237;fico con relaci&#243;n a la seguridad y los principales ajustes sist&#233;micos, ante el TM6m en los pacientes con insuficiencia cardiaca (ICC) refractaria, podr&#237;an minimizar el aparecimiento de respuestas cl&#237;nicas adversas<sup>25</sup> -como las se&#241;ales de intolerancia al ejercicio, las arritmias y complicaciones secundarias-, espec&#237;ficamente presentes en condiciones de reducci&#243;n en el abastecimiento de ox&#237;geno mioc&#225;rdico, muy frecuentes en esa poblaci&#243;n<sup>26,27</sup>. </p>
      <p>El presente estudio tiene por objeto evaluar las respuestas cardiovasculares ante el TM6m y sus posibles relaciones con el estadiamiento cl&#237;nico y el pron&#243;stico cardiovascular. De esa manera, creemos contribuir al perfeccionamiento del control y de la prescripci&#243;n de las intervenciones en esa poblaci&#243;n cardi&#243;pata que aguarda el transplante cardiaco. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Participantes en el estudio</bold>
      </p>
      <p>El grupo de estudio estaba conformado por un total de 12 pacientes (edad 52 &#177; 8 a&#241;os, 10 varones y 2 mujeres) del ambulatorio de transplante cardiaco del Hospital Universitario de la Universidad Federal de S&#227;o Paulo. Los pacientes presentaban diagn&#243;stico cl&#237;nico de insuficiencia cardiaca refractaria, con indicaci&#243;n electiva para transplante cardiaco. Las principales etiolog&#237;as de la insuficiencia cardiaca estaban relacionadas a miocardiopat&#237;as isqu&#233;micas (58,3%) e idiop&#225;ticas (25%). Ocho pacientes (67,7%) estaban en clases funcionales III e IV (NYHA), 10 (83,3%) con comorbidades asociadas y nueve (75%) ya hab&#237;an realizado procedimientos cardiovasculares previos (cinco cirug&#237;as de revascularizaci&#243;n mioc&#225;rdica y cuatro angioplastia transluminal) (<xref ref-type="table" rid="tab01-body3">tab. 1</xref>). La investigaci&#243;n cont&#243; con el previo consentimiento de los pacientes y fue aprobada por el Comit&#233; de &#201;tica e Investigaci&#243;n. </p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt01-es.jpg"/></table-wrap>
      <p>Datos param&#233;tricos continuos representados en promedio &#177; desviaci&#243;n est&#225;ndar; datos categ&#243;ricos o continuos representados en N&#186;, N&#250;mero de pacientes (% del total) &#170;, frecuencia en ocho pacientes con infarto agudo de miocardio, <sup>b </sup>frecuencia en 5 pacientes con revascularizaci&#243;n del miocardio.</p>
      <p>
        <bold>Dise&#241;o y protocolo</bold>
      </p>
      <p>El estudio, caracterizado como una cohorte prospectiva, cont&#243; con 15 pacientes, y se excluyeron a tres de ellos por descompensaci&#243;n cardiovascular y 12 fueron sometidos al protocolo. El estudio estaba conformado por una evaluaci&#243;n cl&#237;nica inicial, con informaciones sobre el estadiamiento cl&#237;nico y cardiovascular, seguido de test de marcha de 6 minutos (TM6m). Tras ello, se siguieron a los pacientes cl&#237;nicamente por 12 meses luego del TM6m. </p>
      <p>
        <bold>Evaluaci&#243;n cl&#237;nica inicial</bold>
      </p>
      <p>Const&#243; de informaciones referentes a la evaluaci&#243;n cl&#237;nica y ecocardiogr&#225;fica como: etiolog&#237;a, presencia de comorbidades y procedimientos cardiovasculares previos, tratamiento cl&#237;nico y funci&#243;n cardiovascular (fracci&#243;n de eyecci&#243;n (%)) y clase funcional (NYHA)<sup>28</sup>. Asimismo, se evaluaron a los pacientes en cuanto al impacto de la insuficiencia cardiaca en la calidad de vida, utiliz&#225;ndose un cuestionario espec&#237;fico para insuficiencia cardiaca, denominado <italic>Minnesota Living with Heart Failure questionnaire</italic> (MLHF)<sup>18</sup>. </p>
      <p>
        <bold>Test de marcha de 6 minutos</bold>
      </p>
      <p>Los pacientes fueron sometidos inicialmente a examen de electrocardiograf&#237;a en reposo, para verificaci&#243;n de la existencia de arritmias. Se realiz&#243; el TM6m -de acuerdo con las directrices de la Asociaci&#243;n Americana de Rehabilitaci&#243;n Cardiovascular y Pulmonar (AACVPR)<sup>29</sup> y las directrices para realizaci&#243;n de ex&#225;menes ergom&#233;tricos de la Sociedad Brasile&#241;a de Cardiolog&#237;a (SBC)<sup>7</sup>- en pista circular de 30 metros de largo, sin seguimiento, recibiendo s&#243;lo las orientaciones estandarizadas a cada minuto. Se monitorearon a los pacientes en los factores que siguen: frecuencia cardiaca (FC, lpm), frecuencia cardiaca de recuperaci&#243;n (FCR, lpm), presi&#243;n arterial (PA, mmHg), saturaci&#243;n perif&#233;rica de ox&#237;geno (SpO<sub>2</sub>, %) y escala de percepci&#243;n de esfuerzo (EP)<sup>30</sup>. Tambi&#233;n se les monitorearon continuamente en cuanto a la electrocardiograf&#237;a por telemetr&#237;a (Quark T12, modelo CO9055-32-99, Cosmed&#174;, Italia), posibilit&#225;ndonos a efectuar el monitoreo instant&#225;neo de eventos que indicaran la suspensi&#243;n del examen. Todav&#237;a se midieron los valores de lactato perif&#233;rico antes y luego del TM6m. Se realiz&#243; la medici&#243;n perif&#233;rica basal tras el per&#237;odo m&#237;nimo de 1 hora, sin la realizaci&#243;n de ejercicios y/o actividades de esfuerzo, y al final, inmediatamente tras el t&#233;rmino de la prueba.</p>
      <p>
        <bold>Seguimiento tras 12 meses del TM6m</bold>
      </p>
      <p>Se siguieron a los pacientes por un periodo de 12 meses tras la realizaci&#243;n del TM6m, a fin de observarse informaciones con relaci&#243;n a la evoluci&#243;n cl&#237;nica, tales como reinternaci&#243;n, descompensaci&#243;n del cuadro cl&#237;nico y mortalidad. </p>
      <p>
        <bold>M&#233;todo estad&#237;stico</bold>
      </p>
      <p>Los datos continuos param&#233;tricos estaban representados por promedio y desviaci&#243;n est&#225;ndar y se los compararon a lo largo del tiempo, mediante la Anova para mediciones repetidas. Se aplic&#243; el post-test de Newman-Keuls para m&#225;s de dos tiempos, o la prueba T de Student en otros casos. Los no param&#233;tricos estaban representados por mediana y percentil, y se los compararon a lo largo del tiempo mediante la prueba de Friedman, con post-test de Muller-Dunn para m&#225;s de dos tiempos, o el Wilcoxon en otros casos. Los datos categ&#243;ricos estaban representados por frecuencia absoluta (n) y frecuencia relativa (%) y se los compararon a lo largo del tiempo mediante la prueba de Mc'Nemar. En el caso de grupos independientes, se utiliz&#243; la prueba Chi-cuadrado. Para verificarse la asociaci&#243;n entre las variables de la prueba con el estadiamiento cl&#237;nico y cardiovascular, se utiliz&#243; el an&#225;lisis de correlaci&#243;n lineal de Pearson, cuyos valores de concordancia admitidos fueron: &gt; 0,75 excelente; &lt; 0,40 pobre; y entre 0,40 y 0,75 moderada. Se tom&#243; en consideraci&#243;n para todo el estudio un riesgo alfa menor o igual al 5%, y riesgo beta de menor o igual al 20%. </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Ocurrencia de arritmias </bold>
      </p>
      <p>Se clasific&#243; la ocurrencia de arritmia de tres formas durante el TM6m. El an&#225;lisis descriptivo, representado por el tipo de arritmia, no revel&#243; exacerbaci&#243;n ante el TM6m (p: 0,228). Ni el an&#225;lisis cualitativo ni el cambio en el estadiamiento de riesgo durante la prueba evidenci&#243; exacerbaci&#243;n, utiliz&#225;ndose clasificaciones en cuanto al origen (p: 0,546) o tipo (0,735) (<xref ref-type="table" rid="es_a11tab02-body3">tab. 2</xref>).</p>
      <p content-type="asset">
        <table-wrap id="es_a11tab02-body3">
          <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt02-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Comportamiento m&#225;ximo ante el TM6m</bold>
      </p>
      <p>Al contrario de la SpO<sub>2</sub> y PA, que no revelaron alteraciones significativas ante el esfuerzo, la FC se ajust&#243; de forma eficiente y fisiol&#243;gica, caracteriz&#225;ndose como principal responsable del ajuste positivo del doble producto cardiaco (<xref ref-type="table" rid="tab03-body3">tab. 3</xref>).</p>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt03-es.jpg"/></table-wrap>
      <p>La distancia promedio recorrida fue de 399,4 &#177; 122,5, con importante incremento en el esfuerzo percibido (14 &#177; 1,5)<sup>31</sup> y evidente variaci&#243;n en el nivel de lactato. En este &#250;ltimo, cuatro individuos alcanzaron niveles superiores a 4 mmol/l, sugiriendo mayor utilizaci&#243;n de metabolismo anaer&#243;bio durante la actividad. Otros tres individuos interrumpieron el test precozmente: el primero por disnea, mareo, palpitaci&#243;n y dolor en miembros inferiores (MMII), a los 285 segundos; el segundo por dolor en MMII, a los 242 segundos; y el tercero por dolor precordial, a los 180 segundos. Los dos &#250;ltimos no presentaron alteraci&#243;n electrocardiogr&#225;fica caracter&#237;stica de isquemia (<xref ref-type="table" rid="tab03-body3">tab. 3</xref>). Tras la interrupci&#243;n, los pacientes podr&#237;an seguir con el examen hasta que se completaran los 360 minutos previstos, s&#243;lo desde entonces que se tom&#243; en consideraci&#243;n la distancia total recorrida.</p>
      <p>
        <bold>Estadiamiento cl&#237;nico y pron&#243;stico cardiovascular</bold>
      </p>
      <p>Tres pacientes murieron en el per&#237;odo de 12 meses de seguimiento, dos de ellos tras reinternaci&#243;n por descompensaci&#243;n cardiovascular, aguardando el transplante cardiovascular, y uno por rechazo tard&#237;o luego del transplante cardiovascular. Los pacientes mantuvieron control peri&#243;dico convencional en ambulatorio de seguimiento cl&#237;nico, pero solamente dos fueron trasplantados durante el per&#237;odo de segmento, siendo que el tiempo promedio de espera a la &#233;poca fue de 21,5 &#177; 4,95 meses. En ese per&#237;odo, seis (50%) manifestaron episodios de empeoramiento del estadiamiento cl&#237;nico, necesitando internaci&#243;n hospitalaria; cinco de ellos (41,67%) por descompensaci&#243;n de la insuficiencia cardiaca y uno (8,33%) por insuficiencia renal. </p>
      <p>El estudio de correlaci&#243;n de todas las variables obtenidas en el TM6m revel&#243; asociaci&#243;n solamente entre la distancia recorrida y la severidad de la arritmia al final del TM6m, con la fracci&#243;n de eyecci&#243;n (FE) (R: 0,7 y -0,83) y clase funcional (CF) (R: 0,73 y 0,73) (<xref ref-type="fig" rid="fig01-body3">fig. 1</xref>). La calidad de vida se revel&#243; moderadamente reducida (31 &#177; 3,33 en 105 puntos), sin embargo, en la evaluaci&#243;n con variables obtenidas con la prueba de marcha, no hubo correlaci&#243;n. </p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gf01-es.jpg"/></fig>
      <p>El an&#225;lisis pareado de las caracter&#237;sticas analizadas antes y durante la prueba de marcha revel&#243; una diferencia significativa entre los individuos que fallecieron en los 12 meses subsiguientes y el grupo superviviente, en cuanto a caracter&#237;sticas como: peso, relaci&#243;n C/C (cintura/cadera), fuerza muscular respiratoria (P<sub>i-m&#225;x. </sub>yP<sub>i-m&#225;x.</sub>), EP (esfuerzo percibido) y la frecuencia cardiaca de recuperaci&#243;n en el 2&#186; minuto (FCR<sub>2</sub>) (<xref ref-type="table" rid="es_a11tab04-body3">tab. 4</xref>). </p>
      <p content-type="asset">
        <table-wrap id="es_a11tab04-body3">
          <graphic xlink:href="1678-4170-abc-92-04-0312-00011-gt04-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>El presente estudio revel&#243; que el TM6m, sin seguimiento, se present&#243; como medida segura con relaci&#243;n a las alteraciones electrocardiogr&#225;ficas y cardiovasculares, en la evaluaci&#243;n de pacientes con insuficiencia cardiaca refractaria. Sin embargo, nuestro estudio refuerza la importancia de la evaluaci&#243;n cl&#237;nica y disfuncional preliminar para estratificaci&#243;n de riesgo. Adem&#225;s de ello, algunas variables relacionadas al desempe&#241;o en el TM6m parecen de hecho estar asociadas al estadiamiento cl&#237;nico actual y la ocurrencia de mortalidad en el seguimiento de un a&#241;o. </p>
      <p>El TM6m ha se presentado como un examen simple, reproductible, de bajo costo y reducida dificultad operacional, con importante correlaci&#243;n con variables cl&#237;nicas, como capacidad funcional, condicionamiento cardiorrespiratorio, clase funcional, calidad de vida y pron&#243;stico cardiovascular<sup>4,6,8-13,17,19-24</sup>. El presente estudio utiliz&#243;, de modo pionero, un sistema de monitoreo electrocardiogr&#225;fico por telemetr&#237;a durante el TM6m en suelo, permitiendo as&#237; la observaci&#243;n en tiempo real de posibles arritmias o se&#241;ales sugestivas de isquemia, que podr&#237;an indicar la suspensi&#243;n de la prueba. Adem&#225;s de ello, se realiz&#243; tambi&#233;n el an&#225;lisis simplificado del lactato perif&#233;rico, a fin de inferir informaciones agudas sobre modulaciones en el metabolismo energ&#233;tico.</p>
      <p>Con hist&#243;rico com&#250;n de presencia de factores de riesgo, procedimientos previos y comorbidades asociadas, los individuos presentaron importante reducci&#243;n de la funci&#243;n cardiovascular, concentr&#225;ndose predominantemente en las clases funcionales III e IV, y teniendo como principal etiolog&#237;a las enfermedades isqu&#233;micas del miocardio. Hist&#243;ricamente, un tercio de los pacientes internados con diagn&#243;stico de insuficiencia cardiaca gasta alrededor de 11 mil millones a cada a&#241;o en tratamiento ambulatorial<sup>1</sup>, que se concentran principalmente en los pacientes en clases funcionales III e IV. As&#237;, mediciones simples, reproductibles y eficientes para evaluaci&#243;n y suporte al tratamiento cardiovascular pueden ser de extrema relevancia, ya que reducen costos y ofrecen un seguimiento m&#225;s calificado. Ya se ha evidenciado en estudios preliminares la calidad de vida que se present&#243; en nuestro estudio -moderadamente reducida y sin correlaci&#243;n con variables del TM6m-, lo que se debe probablemente a la evaluaci&#243;n de solamente un n&#250;mero restricto de pacientes en las diferentes clases funcionales<sup>10</sup>.</p>
      <p>Se realiz&#243; el an&#225;lisis de la ocurrencia de arritmias de tres maneras: </p>
      <p>&#149; Clasificaci&#243;n propuesta por Low y Wolf<sup>32</sup> que considera la severidad de las arritmias ventriculares.</p>
      <p>&#149; Clasificaci&#243;n atrioventricular (AV) que divide las arritmias en ventriculares y supraventriculares<sup>27</sup>. </p>
      <p>&#149; Evaluaci&#243;n cualitativa (descriptiva) de los hallazgos electrocardiogr&#225;ficos<sup>26</sup>. </p>
      <p>Los dos &#250;ltimos an&#225;lisis relatan una mayor incidencia de arritmias en pacientes con reducci&#243;n en el abastecimiento de ox&#237;geno en el miocardio. En el presente estudio, el an&#225;lisis evidenci&#243; alta probabilidad de ocurrencia de arritmias en esa poblaci&#243;n que, sin embargo, no fueron exacerbadas ante el TM6m. Esto sugiere la seguridad del m&#233;todo, y enfatiza la necesidad de una evaluaci&#243;n cl&#237;nica y disfuncional preliminar estratificadora. No obstante, hay que tener bien evaluada la utilizaci&#243;n rutinera de sistemas de monitoreos electrocardiogr&#225;ficos, una vez que el test de marcha tiene por principio ser una prueba simplificada y de f&#225;cil reproductibilidad. </p>
      <p>En el an&#225;lisis del ajuste cardiovascular ante el TM6m, la FC fue la variable que demostr&#243; ajuste m&#225;s expresivo ante la prueba. Dicho comportamiento revela la influencia de la variable en las variaciones del doble producto cardiaco, visto que ellos ya presentan p&#233;rdidas de la funci&#243;n cardiovascular, evidenciada por la reducida fracci&#243;n de eyecci&#243;n ventricular. De esa manera, as&#237; como podr&#237;amos imaginar, la respuesta cronotr&#243;pica fue m&#225;s importante que la inotr&#243;pica en esa poblaci&#243;n<sup>15</sup>. La FCR<sub>2</sub> se encontraba m&#225;s elevada en el grupo que falleci&#243; en los 12 meses de seguimiento. Algunos estudios han descrito la relaci&#243;n del comportamiento de la frecuencia cardiaca de recuperaci&#243;n (FCR) con la funci&#243;n cardiovascular, en que reducciones m&#225;s lentas est&#225;n directamente relacionadas al empeoramiento de la funci&#243;n y la mortalidad cardiovascular, -fen&#243;meno que est&#225; conectado a un desequilibrio del sistema nervioso auton&#243;mico, generalmente producido por hiperestimulaci&#243;n del sistema nervioso simp&#225;tico y reducci&#243;n de la actividad vagal<sup>21,33</sup>- adem&#225;s de calcularse cambios en la capacidad funcional tras un programa de condicionamiento<sup>34</sup>. </p>
      <p>Adem&#225;s de ello, la evaluaci&#243;n simplificada del lactato fue capaz de estimar informaciones adicionales en cuanto al comportamiento del metabolismo energ&#233;tico ante el test de marcha. Fue posible constatar que, a pesar de la frecuencia cardiaca m&#225;xima (FC<sub>m&#225;x.</sub>) haber alcanzado el promedio de s&#243;lo un 66,3 % de lo que se previ&#243;, cuatro de esos pacientes ultrapasaron el valor de 4 mmol/l en el an&#225;lisis del comportamiento del lactato, sugiriendo mayor utilizaci&#243;n de metabolismo anaer&#243;bio. Estudios recientes revelan la relaci&#243;n entre el metabolismo anaer&#243;bio y la capacidad funcional como importante predictor de mortalidad<sup>35,36</sup>. A&#250;n as&#237;, tras el TM6m, los individuos relataron un esfuerzo percibido promedio de 14,3 &#177; 1,55 en 20 puntos, lo que corresponde a un esfuerzo m&#225;s pr&#243;ximo de agotador, resultado &#233;ste compatible con el esfuerzo relatado en otros estudios<sup>9</sup>. Esos hallazgos nos permiten inferir un posible equ&#237;voco en la estimaci&#243;n de la frecuencia cardiaca m&#225;xima para esos pacientes con importante limitaci&#243;n funcional y que, en su mayor&#237;a (83,3%), utilizaban tratamiento betabloqueante<sup>37,38</sup>. </p>
      <p>Como se pudo evidenciar en la evaluaci&#243;n cl&#237;nica inicial, las variables que m&#225;s se diferenciaron en los individuos que fallecieron en los 12 meses subsiguientes, con relaci&#243;n a los que sobrevivieron, fueron el peso, la fuerza muscular y la relaci&#243;n cintura/cadera. El peso y la fuerza muscular son importantes marcadores en esa poblaci&#243;n, cuando se tiene en cuenta que, con la evoluci&#243;n de la insuficiencia cardiaca, ellos desarrollan un aumento de la demanda energ&#233;tica metab&#243;lica asociada a una perceptible degradaci&#243;n m&#250;sculo-esquel&#233;tica. De ese modo, se puede generar un estadio funcional denominado caquexia cardiaca, interfiriendo de forma negativa en el condicionamiento cardiorrespiratorio y, consecuentemente, en la calidad de vida y en el pron&#243;stico cardiovascular<sup>2,3</sup>. </p>
      <p>Ya el an&#225;lisis de la relaci&#243;n entre el TM6m y el estadiamiento cl&#237;nico y pron&#243;stico cardiovascular revel&#243; primariamente que -pese a pertenecer a un grupo aparentemente homog&#233;neo, ambos igualmente ya elegibles para el transplante cardiaco- &#233;stos presentaban una capacidad funcional, estimada por la distancia recorrida, muy diversificada, principalmente para los cuatro pacientes que recorrieron una distancia inferior a 300 metros. En los d&#237;as actuales, se sabe que los individuos con insuficiencia cardiaca que caminan menos que 300 metros tienen un pron&#243;stico muy perjudicado<sup>14-16</sup>. Adem&#225;s de ello, en nuestro estudio, la distancia m&#225;xima recorrida en el TM6m demostr&#243; importante correlaci&#243;n con algunas de las caracter&#237;sticas cl&#237;nicas cl&#225;sicas como la fracci&#243;n de eyecci&#243;n (r = 0,70) y la clase funcional (r = 0,73). A pesar de algunos estudios plantear cuestiones sobre la utilidad del test como medida de estadiamiento cl&#237;nico cardiovascular, la mayor parte de los ensayos cl&#237;nicos randomizados es a favor del valor diagn&#243;stico en los pacientes con insuficiencia cardiaca<sup>10,15</sup>. </p>
      <p>Por fin, en la comparaci&#243;n del grupo superviviente con los que fallecieron, se pudo observar que la relaci&#243;n entre la distancia recorrida y el esfuerzo percibido (metros/EP), el esfuerzo percibido (EP) y la frecuencia cardiaca de recuperaci&#243;n (FCR, lpm) se mostraron las variables que mejor se diferenciaron. </p>
      <p>El presente estudio tuvo algunas limitaciones. Inicialmente, evaluamos una muestra relativamente peque&#241;a de pacientes con indicaci&#243;n electiva para transplante cardiaco. Sin embargo, pese a haberse demostrado resultados relevantes en esta investigaci&#243;n, resaltamos la dificultad en el acceso a esa poblaci&#243;n: durante todo el periodo de realizaci&#243;n del estudio, la Asociaci&#243;n Brasile&#241;a de Transplante de &#211;rganos (ABTO) contabiliz&#243; solamente 60 transplantes cardiacos en el Estado de S&#227;o Paulo, para un total de 98 personas registradas<sup>39</sup>. De ese modo, la poblaci&#243;n evaluada correspondi&#243; al 12% del total de pacientes registrados, se&#241;alando la importancia de la proposici&#243;n de estudios multic&#233;ntricos en el futuro. Adem&#225;s de ello, el an&#225;lisis simplificado para comparaci&#243;n transversal en sustituci&#243;n a un an&#225;lisis detallado sobre la mortalidad tambi&#233;n se justific&#243; por disponerse de un n&#250;mero restricto pacientes. </p>
      <p>En suma, el comportamiento cl&#237;nico y electrocardiogr&#225;fico sugiere que el m&#233;todo es seguro, pero se lo puede considerar de alta intensidad para algunos pacientes con insuficiencia cardiaca severa. Variables relacionadas al desempe&#241;o en el TM6m pueden estar asociadas con la mortalidad en el seguimiento de un a&#241;o. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Gerson Cipriano Jr., por la Unifesp.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
